Evidence map›Paper›PMID 29540489›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018

Survivin Monoclonal Antibodies Detect Survivin Cell Surface Expression and Inhibit Tumor Growth

Robert A Fenstermaker, Sheila A Figel, Jingxin Qiu, Tara A Barone, Sanam S Dharma, Evan K Winograd, Phillip M Galbo, Laura M Wiltsie, Michael J Ciesielski

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05163080 (Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma), which is not on this map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05163080 phase2unknown statusnot on this mapstarted 2021, after this paper: background citation

Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)

TypeinterventionalSponsorMimiVax, LLCRan2021 to 2024Enrolled247ConditionsNewly Diagnosed GlioblastomaArmsSurVaxM
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 42 citations in OpenAlex.

  1. Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Trial
  2. Dynamic translocation of Inside-Out proteins to the cell surface underlies cellular adaptation to cancer-induced stress.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Risk Factors from Pregnancy to Adulthood in Multiple Sclerosis Outcome.International journal of molecular sciences · 2022
    Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Robert A FenstermakerDepartment of Neurosurgery, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Sheila A FigelDepartment of Neurosurgery, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Jingxin QiuDepartment of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Tara A BaroneDepartment of Neurosurgery, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Sanam S DharmaDepartment of Neurosurgery, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Evan K WinogradDepartment of Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, New York.
Phillip M GalboDepartment of Neurosurgery, Roswell Park Comprehensive Cancer Center, Buffalo, New York.ORCID 0000-0002-5391-598X
Laura M WiltsieDepartment of Pediatrics, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, New York.
Michael J CiesielskiDepartment of Neurosurgery, Roswell Park Comprehensive Cancer Center, Buffalo, New York. michael.ciesielski@roswellpark.org.
Roswell Park Comprehensive Cancer Center · USUniversity at Buffalo, State University of New York · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6M
Targeting the anti-apoptotic protein survivin in gliomaR21NS049309 · NINDS · ROSWELL PARK CANCER INSTITUTE CORP · PI FENSTERMAKER, ROBERT A · 2004 to 2005
$470k
NCI NIH HHS P30 CA016056NINDS NIH HHS R21 NS049309
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Biomarkers, TumorAnimalsAntibodies, MonoclonalAntibody AffinityAntibody-Dependent Cell CytotoxicityAntibody SpecificityAntineoplastic Agents, ImmunologicalCell Line, TumorCell MembraneDisease Models, AnimalGene ExpressionHumansMaleMelanoma, ExperimentalMembrane MicrodomainsMiceAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalBiomarkers, TumorPeptidesRecombinant Fusion ProteinsSurvivin

Identifiers

PMID29540489
PMCPMC5984688
OpenAlexW2791905817

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.